 Home > Active Ingredient News > Digestive System Information > Front Oncol: TACE combined with sorafenib or apatinib in the treatment of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT)

Front Oncol: TACE combined with sorafenib or apatinib in the treatment of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT)

 Last Update: 2021-11-03
 Source: Internet
 Author: User

Tags

prism data analysis

blood vessel tumor

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Hepatocellular carcinoma (HCC) is a highly aggressive malignant tumor with a poor prognosis

From June 2015 to March 2020, a total of 89 patients with advanced liver cancer who received continuous sorafenib-TACE (S-TACE) or apatinib-TACE (A-TACE) treatment with PVTT were enrolled

89 HCC patients with PVTT received S-TACE (n = 38) and A-TACE (n = 51)

In the S-TACE group, patients with complete remission (CR), partial remission (PR), stable disease (SD), and disease progression (PD) were 1 case, 10 cases, 10 cases, and 11 cases, respectively

Efficacy evaluation

According to the type of PVTT to further analyze the efficacy

TTP

At the end of the study, a total of 54 patients had died (22 of the 32 patients in the S-TACE group (81.

Univariate analysis showed Child-Pugh classification (HR, 2.

Univariate analysis showed ECOG score (HR, 1.

Except for post-embolization syndrome, no serious adverse events related to TACE surgery were observed
.
The most common adverse reactions in the two groups were similar, including hand-foot skin reactions, diarrhea, high blood pressure, proteinuria, and fatigue
.
Most patients in the two groups had grade 1 to 3 adverse reactions, and 3 patients in both groups had grade 4 to 5 reactions
.
All patients with adverse events were relieved or eliminated after dose reduction or symptomatic treatment
.
No fatal adverse events related to treatment were observed
.

Adverse reactions

In summary, studies have shown that S-TACE and A-TACE have the same prognosis in patients with primary liver cancer with PVTT, providing this type of patients with another effective and safe method besides conventional S-TACE
.
Studies have shown that S-TACE and A-TACE have the same prognosis in patients with primary liver cancer with PVTT, providing this type of patients with another effective and safe method besides conventional S-TACE
.
Studies have shown that S-TACE and A-TACE have the same prognosis in patients with primary liver cancer with PVTT, providing this type of patients with another effective and safe method besides conventional S-TACE
.

Original source:

Cao Y, Sun T, Guo X, Ouyang T, Kan X, Chen L, Liang B, Wang M and Zheng C (2021) Sorafenib Versus Apatinib Both Combined Transarterial Chemoembolization for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Comparative Retrospective Study.
Front.
Oncol.
11:673378.
doi: 10.
3389/fonc.
2021.
673378

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.